Showing all news

Respiratory ‘Call for Targets’ launched

‘Call for targets’ launched to find new therapeutic concepts for treatment of respiratory disease, including conditions such as allergy, acute respiratory distress syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, and cystic fibrosis.

2 March 2015

Posters presented at Pharmacology 2014

‘A novel high throughput assay to identify activators of the two-pore domain potassium channel TRESK’ and ‘Identification of small molecule melanocortin 2 receptor antagonists as potential therapeutics for Cushing’s disease’.

19 January 2015

Kick-starting stalled drugs for brain diseases

Guest blog on BIA website: In November 2014, MRC Technology and charity partners launched a consortium to uncover promising drugs in pharma libraries that could be developed to treat brain diseases. Mike Johnson, Divisional Director, Corporate Partnerships, MRC Technology, discusses sharing the risk of development and breathing a new lease of life into stalled drugs as part of the Neurodegeneration Medicines Acceleration Programme (Neurodegeneration MAP). Read the blog.

13 January 2015

MRC Technology to manage Diabetes UK’s IP

MRC Technology has signed an agreement with Diabetes UK to manage its intellectual property (IP). The partnership will enable Diabetes UK to benefit from MRC Technology’s expertise in IP management, translation and drug discovery, allowing the charity to maximise benefits to patients and return on investment from its research portfolio.

7 January 2015

MRC Technology welcomes launch of Knowledge Quarter

MRC Technology is a member of the newly launched Knowledge Quarter, set up to create a vibrant knowledge hub by bringing together organisations that are actively involved in the advancement and dissemination of knowledge.

4 December 2014

MRC Technology and Shandong International Biotechnology Park (China) to cooperate in new drug for Alzheimer’s

MRC Technology and Shandong International Biotechnology Park (BIOasis) have signed a partnership agreement for the development of a new Alzheimer’s drug. Signed by Fu Fenghua, General Manager of BIOasis and Michael Dalrymple, Director of Business Development at MRC Technology, the development of a new drug for Alzheimer’s could be significant to over 35 million people currently affected by the disease. Financial terms have not been disclosed.

2 December 2014
Showing all news